CalciMedica Discontinues Phase 2 KOURAGE Trial for Auxora in AKI Due to Safety Concerns
CALC has more than doubled off its 52-week low of $1.42.
Summary
CalciMedica announced the discontinuation of its Phase 2 KOURAGE clinical trial for Auxora in acute kidney injury (AKI) following an Independent Data Monitoring Committee recommendation due to a safety concern.
Key Events · Product Development and Regulatory · CALC
-
Phase 2 Trial Discontinuation
CalciMedica has discontinued its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF).
-
Safety Concern Identified
The decision follows a recommendation from the trial's Independent Data Monitoring Committee (IDMC), which identified a safety concern warranting reevaluation of the study design, particularly patient enrollment criteria.
-
No Drug-Related Deaths Reported
The company noted that no deaths in the trial were assessed as related to the study drug (Auxora or placebo), and no serious adverse events met criteria for expedited FDA reporting.
-
Future Plans for Auxora in AKI
CalciMedica plans a comprehensive review of the unblinded clinical data to assess the impact of various factors on patient outcomes, which is expected to inform how future clinical evaluation of Auxora in AKI may proceed.
Analysis · CALC · Life Sciences
CalciMedica's decision to discontinue its Phase 2 KOURAGE clinical trial for Auxora in acute kidney injury (AKI) is a significant setback for the company's lead product candidate in this indication. While the company notes no drug-related deaths or serious adverse events requiring expedited FDA reporting, the Independent Data Monitoring Committee's recommendation to reevaluate the study design due to a safety concern introduces substantial uncertainty and delays for Auxora's development in AKI. Investors should monitor the comprehensive review of unblinded data for insights into potential future trial modifications, as this program's viability in AKI is now in question. The company's other programs, including a pivotal trial for Auxora in acute pancreatitis and CM5480 for pulmonary arterial hypertension, become more critical following this development.
At the time of this filing, CALC was trading at $5.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.8M. The 52-week trading range was $1.42 to $7.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.